Jan. 29 at 11:44 AM
Oppenheimer⬆️
$DNTH's PT to
$125 from
$62 and reiterated at Outperform.
$RNAC $ARGX $NVS AZN
$VRTX TAK
Oppenheimer said in its note:
Dianthus shares have jumped off the starting line this year, up 22% vs. XBI's 5% following CEO Marino Garcia's commentary at January's annual healthcare conference on potential superiority vs. competitor complement inhibitors, and pricing expectations.
We caught up with management ahead of the 2026 setup and see substantial value creation ahead. Catalysts begin with mid-year update on claseprubart's Phase 3 CIDP interim analysis followed by Phase 2 MMN data plus a first-look at DNTH212 in healthy volunteers in 2H26. We see little current value assigned to '212/MMN, and despite substantial share appreciation since the MG look, we believe DNTH shares are just beginning their ascent as comfort builds around potentially superior CIDP/MMN profiles, and as visibility into DNTH212's total product profile grows.
